<DOC>
	<DOCNO>NCT00938730</DOCNO>
	<brief_summary>The purpose study investigate optimal daily dose dose regimen YM150 subject non-valvular atrial fibrillation ( NVAF ) , primarily base safety tolerability data .</brief_summary>
	<brief_title>A Study Evaluating Safety Tolerability YM150 Compared Warfarin Subjects With Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subject paroxysmal , permanent persistent Nonvalvular Atrial Fibrillation ( NVAF ) Subject prothrombin time international normalize ratio ( INR ) 2.0 baseline visit Subject current recent ( within 12 month prior screen ) history stroke and/or systemic embolism ( include TIA ) Subject active bleeding condition associate increase risk bleeding Subject NVAF secondary reversible disorder ( e.g . thyrotoxicosis ) Subject indication warfarin AF ( include plan cardioversion ) Subject diagnosis Acute Coronary Syndrome ( ACS ) , coronary artery bypass graft ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) within previous 3 month screen Subject diagnosis leave ventricular aneurysm atrial myxoma Subject require use prohibit previous concomitant medication ( i.e. , thrombolytic [ tissue Plasminogen Activator ( tPA ) , streptokinase ] , antiplatelet agent [ cilostazol , clopidogrel , ticlopidine , dipyridamole ] , anticoagulant [ vitamin K antagonist , heparin , unfractionated low molecular weight heparin , fondaparinux , thrombin inhibitor ] chronic use nonsteroidal antiinflammatory drug [ NSAIDs ] acetylsalicylic acid use &gt; 100 mg/day ) . ( see Section 5.1.3 Appendix 1 detail ) Subject active infective endocarditis Subject plan invasive procedure potential bleed Subject participate another clinical trial investigational drug ( include placebo ) device within 30 day ( limit set national law , whichever long ) signing inform consent present study Subject participate YM150 clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Nonvalvular Atrial Fibrillation ( NVAF )</keyword>
	<keyword>Factor Xa Inhibitor</keyword>
	<keyword>Stroke</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Transient Ischemic attack</keyword>
	<keyword>Anticoagulants</keyword>
	<keyword>Prevention</keyword>
	<keyword>YM150</keyword>
	<keyword>Warfarin</keyword>
</DOC>